Home
Storia in 2 fonti
Cytokinetics heart drug scores in closely watched trial
Myqorzo’s success in “non-obstructive” hypertrophic cardiomyopathy separates it from Bristol Myers Squibb’s rival Camzyos and opens up a multibillion-dollar market opportunity.
- ·
biopharmadive.com
Cytokinetics heart drug scores in closely watched trial
Myqorzo’s success in “non-obstructive” hypertrophic cardiomyopathy separates it from Bristol Myers Squibb’s rival Camzyos and opens up a multibillion-dollar market opportunity.
- ·
statnews.com
Cytokinetics drug Myqorzo meets twin efficacy goals in study of genetic heart disease
A Cytokinetics heart disease drug — already approved in one indication — succeeded in another Phase 3 trial, a potential boost for sales.